165 related articles for article (PubMed ID: 7339332)
1. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man.
Davison SC; Hyman N; Prentis RA; Dehghan A; Chan K
Methods Find Exp Clin Pharmacol; 1980 Apr; 2(2):77-82. PubMed ID: 7339332
[TBL] [Abstract][Full Text] [Related]
2. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
Chan K; Davison SC; Dehghan A; Hyman N
Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
[TBL] [Abstract][Full Text] [Related]
3. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.
Chan K; Williams NE; Baty JD; Calvey TN
J Chromatogr; 1976 May; 120(2):349-58. PubMed ID: 1270556
[TBL] [Abstract][Full Text] [Related]
4. The simultaneous determination of pethidine and norpethidine in biofluids by nitrogen selective gas chromatography.
Tse J; Chan K
Methods Find Exp Clin Pharmacol; 1981; 3(2):99-104. PubMed ID: 7230982
[TBL] [Abstract][Full Text] [Related]
5. The simultaneous determination of neostigmine and pyridostigmine in plasma [proceedings].
Davison SC; Prentis RA; Dehghan A; Chan K
Br J Clin Pharmacol; 1980 Mar; 9(3):311P-312P. PubMed ID: 7362760
[No Abstract] [Full Text] [Related]
6. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
7. Determination of pyridostigmine bromide and its metabolites in biological samples.
Zhao B; Moochhala SM; Lu J; Tan D; Lai MH
J Pharm Pharm Sci; 2006; 9(1):71-81. PubMed ID: 16849010
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
9. Plasma clearance of neostigmine and pyridostigmine in the dog.
Baker PR; Calvey TN; Chan K; Macnee CM; Taylor K
Br J Pharmacol; 1978 Jul; 63(3):509-12. PubMed ID: 667495
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of cholinesterase inhibitors.
Aquilonius SM; Hartvig P
Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
[TBL] [Abstract][Full Text] [Related]
11. Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds: determination of pyridostigmine, neostigmine and edrophionium in biological fluids.
De Ruyter MG; Cronnelly R
J Chromatogr; 1980 Aug; 183(2):193-201. PubMed ID: 7400278
[TBL] [Abstract][Full Text] [Related]
12. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
13. Post-varicella myasthenia gravis.
Saha A; Batra P; Vilhekar KY; Chaturvedi P
Singapore Med J; 2007 Jun; 48(6):e177-80. PubMed ID: 17538742
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
15. Congenital myasthenia gravis.
Nizamani NB; Talpur KI; Memon MN
J Coll Physicians Surg Pak; 2013 Jul; 23(7):517-8. PubMed ID: 23823963
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment of myasthenia gravis].
de Assis JL
Rev Paul Med; 1965 Oct; 67(4):231-42. PubMed ID: 5848156
[No Abstract] [Full Text] [Related]
17. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
18. Plasma clearance of neostigmine and pyridostigmine in rats with ligated renal pedicles.
Burdfield PA; Calvey TN
Eur J Pharmacol; 1973 Nov; 24(2):252-5. PubMed ID: 4765748
[No Abstract] [Full Text] [Related]
19. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.
NOWELL PT; SCOTT CA; WILSON A
Br J Pharmacol Chemother; 1962 Jun; 18(3):617-24. PubMed ID: 14480648
[TBL] [Abstract][Full Text] [Related]
20. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.
Yu QS; Holloway HW; Luo W; Lahiri DK; Brossi A; Greig NH
Bioorg Med Chem; 2010 Jul; 18(13):4687-93. PubMed ID: 20627738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
